Replies to post #142791 on Biotech Values

[DewDiligence]

GSK combo maybe will show how two average TKIs combined together can produce more dramatic result than each on its own.

It’s notable that this has rarely if ever worked with combinations of mAbs.

[genisi]

GSK will present dabrafenib monotherapy in ph3 melanoma result at ASCO as well. Would be interesting to see efficacy relative to Zelboraf. If I remember correctly the earlier efficacy result wasn't as striking as Zelboraf.

Thanks for the pointer, I've skipped it as the abs. isn't available yet. I don't think GSK ever presented PFS and OS data from phase II, so are you talking about phase I data?